What is ICD-10 code C92.02?

C92.02 is the ICD-10-CM diagnosis code for Acute myeloblastic leukemia, in relapse. An acute blood cancer of myeloid cells that has returned after a period of remission. It belongs to the ICD-10-CM chapter for neoplasms (c00-d49). C92.02 is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. C92.02 is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. C92.02 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. C92.02 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

What is the V28 vs V24 difference for C92.02?

CMS phased in the V28 risk adjustment model over payment years 2024 (33%), 2025 (67%), and 2026 (100%), replacing V24. V28 consolidates HCC categories, removes some lower-acuity conditions, and recalibrates RAF weights across the entire model. For C92.02, V28 maps to Metastatic Cancer and Acute Leukemia at RAF 0.368 while V24 mapped to Metastatic Cancer and Acute Leukemia at RAF 2.484. Both models can still appear in legacy data and in payer-specific lookback periods.

What should coders know when reporting C92.02?

Document must clearly indicate the cancer has recurred after prior remission Distinguish from initial diagnosis by confirming previous remission status in patient history Because C92.02 maps to a payment HCC, the documentation must also satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's risk adjustment score.

C92.02 ICD-10 Code: Acute myeloblastic leukemia

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC92.02Effective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C92.02

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Acute myeloblastic leukemia, in relapse

An acute blood cancer of myeloid cells that has returned after a period of remission.

Buddy Insight

Acute myeloblastic leukemia in relapse indicates return of AML after previously achieving remission, which is one of the most serious clinical scenarios in hematologic oncology.

CMS-HCC V28

Mapped

HCC 17

Metastatic Cancer and Acute L...

RAF 0.368

CMS-HCC V24

Mapped

HCC 8

Metastatic Cancer and Acute L...

RAF 2.484

ACA/HHS

Not risk-adjusted for this model/period.

RAF 0

ESRD/PACE

Mapped

HCC 8

Metastatic Cancer and Acute L...

RAF 0.0

RXHCC

Mapped

HCC 19

Lymphoma and Other Cancers

RAF 0.0

Code Trumping

Basket needed

Compare selected patient codes to show trumped or trumps impact.

Code Book Path

Official

C92Myeloid leukemia

C92.0Acute myeloblastic leukemia

C92.02Acute myeloblastic leukemia, in relapse

Inclusion Terms

Official

Acute myeloblastic leukemia, minimal differentiation
Acute myeloblastic leukemia (with maturation)
Acute myeloblastic leukemia 1/ETO
Acute myeloblastic leukemia M0
Acute myeloblastic leukemia M1

Excludes 2

Official

ICD-10-CM does not list Excludes 2 notes for C92.02 in this effective period.

Related Child Codes

Official

C92.00Acute myeloblastic leukemia, not having achieved remission

C92.01Acute myeloblastic leukemia, in remission

Includes

Official

ICD-10-CM does not list Includes notes for C92.02 in this effective period.

Excludes 1

Official

acute exacerbation of chronic myeloid leukemia (C92.10)
refractory anemia with excess of blasts not in transformation (D46.2-)

Code First

Official

ICD-10-CM does not list Code First sequencing instructions for C92.02 in this effective period.

Use Additional

Official

ICD-10-CM does not list Use Additional Code instructions for C92.02 in this effective period.

Code Also

Official

ICD-10-CM does not list Code Also instructions for C92.02 in this effective period.

Buddy Documentation Tip

HCC Buddy guidance

Documentation must confirm prior complete remission and current evidence of relapse (rising blast count, new extramedullary disease).

Updated cytogenetic and molecular testing at relapse is essential as clonal evolution is common and may reveal new therapeutic targets or adverse features.

Duration of first remission, prior treatment regimens, and transplant candidacy assessment must be documented.

MEAT Support

HCC Buddy guidance

Documentation must confirm prior complete remission and current evidence of relapse (rising blast count, new extramedullary disease).

Updated cytogenetic and molecular testing at relapse is essential as clonal evolution is common and may reveal new therapeutic targets or adverse features.

Duration of first remission, prior treatment regimens, and transplant candidacy assessment must be documented.

Audit Caution

HCC Buddy guidance

Distinguish relapse (recurrence after documented CR) from refractory disease (never achieved remission). Early relapse (within 6-12 months of CR) carries a worse prognosis than late relapse and may influence treatment decisions and transplant candidacy. Molecular features may change at relapse

do not assume the same cytogenetic profile as initial diagnosis. Ensure blast count confirms AML rather than myelodysplastic syndrome.

Common Mistakes

HCC Buddy guidance

C92.00 (AML not in remission) is for primary refractory disease.

C92.01 (AML in remission) is for controlled disease.

More specific relapse codes should be used when applicable: C92.42 (APL in relapse), C92.52 (acute myelomonocytic leukemia in relapse), C92.62 (AML with 11q23-abnormality in relapse).

Last updated: FY2026 ICD-10-CM Apr update, Apr 1, 2026 through Sep 30, 2026. CMS-HCC V28 is 100% phased in for payment year 2026.

Is C92.02 an HCC code?

Yes. C92.02 maps to Metastatic Cancer and Acute Leukemia under the CMS-HCC V28 risk adjustment model (and Metastatic Cancer and Acute Leukemia under V24).

HCC Category Mapping

V28HCC 17, Metastatic Cancer and Acute Leukemia

0.368

V24HCC 8, Metastatic Cancer and Acute Leukemia

2.484

ESRDHCC 8, Metastatic Cancer and Acute Leukemia

0.000

RxHCCHCC 19, Lymphoma and Other Cancers

0.000

RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

MEAT Criteria for C92.02

For C92.02to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C92.02 during that encounter, not just copy-forwarded from a problem list.

What This Code Means

C92.02 is the ICD-10-CM diagnosis code for acute myeloblastic leukemia, in relapse. An acute blood cancer of myeloid cells that has returned after a period of remission. C92.02 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C92.02 maps to Metastatic Cancer and Acute Leukemia (HCC 17) with a community, non-dual, aged base RAF weight of 0.368. Under the older V24 model, C92.02 mapped to the same category but with a base RAF weight of 2.484, V28 recalibrated weights across the entire model. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

Document must clearly indicate the cancer has recurred after prior remission. Because C92.02 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C92.02 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•Document must clearly indicate the cancer has recurred after prior remission
•Distinguish from initial diagnosis by confirming previous remission status in patient history

Clinical Significance

Acute myeloblastic leukemia in relapse indicates return of AML after previously achieving remission, which is one of the most serious clinical scenarios in hematologic oncology. Relapsed AML carries a poor prognosis, with long-term survival rates of 10-30% depending on the duration of first remission and molecular features at relapse. Treatment typically involves intensive salvage chemotherapy followed by allogeneic stem cell transplantation when feasible.

Documentation Requirements

✓Documentation must confirm prior complete remission and current evidence of relapse (rising blast count, new extramedullary disease).
✓Updated cytogenetic and molecular testing at relapse is essential as clonal evolution is common and may reveal new therapeutic targets or adverse features.
✓Duration of first remission, prior treatment regimens, and transplant candidacy assessment must be documented.

Commonly Confused Codes

•C92.00 (AML not in remission) is for primary refractory disease.
•C92.01 (AML in remission) is for controlled disease.
•More specific relapse codes should be used when applicable: C92.42 (APL in relapse), C92.52 (acute myelomonocytic leukemia in relapse), C92.62 (AML with 11q23-abnormality in relapse).